Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Boston Scientific entered into a definitive agreement to acquire Vertiflex for $465 million upfront cash plus additional payments contingent on commercial…
Boston Scientific announced the $465M upfront acquisition with additional milestones over three years, highlighting Superion as the only FDA-approved…
Boston Scientific closed its acquisition of Vertiflex on June 11, 2019; $465M upfront cash plus payments contingent on commercial milestones over three years.
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Boston Scientific agreed to acquire Vertiflex for $465M upfront in cash plus contingent payments through 2021 tied to commercial milestones. Adds the Superion Indirect Decompression System for moderate lumbar spinal stenosis to its pain-management portfolio.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Boston Scientific Corporation / Vertiflex, Inc. (this deal) | 2019 | $465M | — |
| Boston Scientific Corporation / Endo International plc (American Medical Systems Men's Health and Prostate Health) | 2015 | $1.6B | 82 |
| Boston Scientific Corporation / BTG plc | 2018 | $4.2B | 78 |
| Boston Scientific Corporation / Advanced Bionics Corporation | 2004 | $740M | 26 |
| Watson Pharmaceuticals (Actavis Inc.) / Actavis plc | 2012 | $5.9B | 97 |
| Kohlberg Kravis Roberts & Co. / PRA International (Genstar Capital) | 2013 | $1.3B | 91 |
| Stryker Corporation / MAKO Surgical Corp. | 2013 | $1.6B | 91 |
← Browse all deals · How we score deals
More: 2019 deals · Boston Scientific Corporation deals · Other deals